SIC
ANIK icon

SJS Investment Consulting’s Anika Therapeutics ANIK Stock Holding History

SJS Investment Consulting’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$469 Buy
32
+17
+113% +$252 ﹤0.01% 2289
2026
Q1 		$218 Buy
+15
New +$174 ﹤0.01% 1961

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
HIM
Hillsdale Investment Management Toronto, Ontario, Canada $4.39B AUM 72.96% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

SJS Investment Consulting's ANIK Position: Q2 2026 in Review

SJS Investment Consulting increased its Anika Therapeutics (ANIK) stake by 113% in Q2 2026, buying an estimated $252 and bringing the position to 32 shares worth $469. The position accounts for ﹤0.01% of the portfolio, ranked #2289.

SJS Investment Consulting first reported a position in ANIK in Q1 2026 and has held it in 2 quarters since. 68 funds tracked by Wall St. Rank hold ANIK as of Q2 2026.

  • SJS Investment Consulting held 32 shares of Anika Therapeutics worth $469 as of Q2 2026.
  • SJS Investment Consulting bought 17 Anika Therapeutics shares in Q2 2026, an estimated $252.
  • Anika Therapeutics made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #2289 holding.
  • SJS Investment Consulting first reported a position in Anika Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 68 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.